This paper is concerned with the challenge of enabling the use of confidential or private data for research and policy analysis, while protecting confidentiality and privacy by reducing the risk of disclosure of sensitive information. Traditional solutions to the problem of reducing disclosure risk include releasing de-identified data and modifying data before release. In this paper we discuss the alternative approach of using a remote analysis server which does not enable any data release, but instead is designed to deliver useful results of user-specified statistical analyses with a low risk of disclosure. The techniques described in this paper enable a user to conduct a wide range of methods in exploratory data analysis, regression and survival analysis, while at the same time reducing the risk that the user can read or infer any individual record attribute value. We illustrate our methods with examples from biostatistics using publicly available data. We have implemented our techniques into a software demonstrator called Privacy-Preserving Analytics (PPA), via a web-based interface to the R software. We believe that PPA may provide an effective balance between the competing goals of providing useful information and reducing disclosure risk in some situations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2008.04.001 | DOI Listing |
Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Intern Emerg Med
January 2025
Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY, USA.
Recent data on methods used by adults to stop smoking can inform tobacco control policies. Nationally representative Centers for Disease Control and Prevention survey data from the 2022 National Health Interview Survey (N = 27,651) were used to analyze populations of US adults who self-reported having stopped smoking cigarettes for 6 months or longer in the last year and the methods they used, or who did not stop smoking but tried in the last year (N = 1735). In 2022, an estimated 2.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, China.
Purpose: To explore the dynamic and parametric characteristics of [F]F-FAPI-42 PET/CT in lung cancers.
Methods: Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (K, K, K, K, K) calculated.
Andes Pediatr
October 2024
Universidad de Antioquia, Medellín, Colombia.
Unlabelled: Gender identity is configured from childhood.
Objective: to explore the experience in the construction of a diverse gender in adolescence in its family and social context.
Subject And Method: Exploratory qualitative study that used the Grounded Theory method and its analytical techniques of coding, categorization, and constant comparison.
Andes Pediatr
August 2024
Facultad de Salud, Universidad Santiago de Cali, Cali, Colombia.
Unlabelled: High-frequency oscillatory ventilation with volume guarantee (HFOV-VG) is a ventilatory mode that controls small tidal volumes at supraphysiological frequencies, potentially beneficial for preterm infants with respiratory distress syndrome (RDS).
Objective: To identify the physiological and clinical effects of HFOV-VG in preterm newborns with RDS, compared with conventional HFOV.
Method: Exploratory review of studies published between 2019 and 2023 of preterm newborns from 23 to 36 weeks of gestation with RDS, weighing ≥ 450g, with invasive HFOV support, using PRISMA flow diagram.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!